Insulin Independence Revolutionary Phase 3 Trial
Giving Type 1 Diabetics the Promise of a Needle-free Life

Charleston, SC (June 23, 2015) – Perle Bioscience, Inc. (www.perlebioscience.com) announces enrollment for the Insulin Independence Trial (IIT). This trial is the first and only Phase 3 trial to test a combination therapy in type 1 diabetics.

The end goal of the IIT will yield a medical breakthrough: insulin independence. The combination therapy will jumpstart the pancreas in type 1 diabetes patients so that the pancreas produces insulin and eliminates the need for insulin injections.

According to Dr. Claresa Levetan, Founder and Chief Scientific Officer of Perle Bioscience, “For patients with type 1 diabetes, the combination therapy patented by Perle Bioscience could end diabetes as we now know it.” “Our goal is to eliminate the need for patients with type 1 diabetes to receive insulin injections and the mission of Perle Bioscience is to have this become a reality.”

PRL001, the combination therapy drug in the IIT sponsored by Perle Bioscience, combines the usage of an immune tolerance agent and a therapy for pancreatic beta cell regeneration. Each therapy is already FDA (Federal Drug Administration) and EMA (European Medical Agency) approved. Both classes of therapies have been used in more than 1,000 patients with new onset type 1 diabetes, but never used together. This novel therapy is expected to result in the ability of the pancreas to produce insulin with new beta cells protected from immune attack.

“The ultimate goal is insulin independence, which means type 1 patients go back to producing their own insulin from their own pancreas” says Dr. Ryan Fiorini, President & CEO of Perle Bioscience. “The success of this trial would result in a needle-free treatment, and will be life changing for those living with type 1 diabetes.”

The Insulin Independence Trial launches in Europe, with the goal of U.S. patient enrollment in a similar U.S. based trial based upon future FDA approval. Seven designated trial sites are located within Italy, with two additional sites to be scheduled outside of Italy. The lead trial site is in Rome at the Università Campus Bio-medico di Roma, and will be conducted by the trial’s lead investigator Dr. Paolo Pozzilli.
Perle Bioscience is a privately held research & development company. For more information on Perle Bioscience, please visit: www.PerleBioscience.com.

About Perle Bioscience:
Founded in 2013 by Dr. Cairesa Levetan, Perle Bioscience is dedicated to finding original treatments for type 1 diabetes with the ultimate goal of eliminating the disease all together by novel approaches to beta regeneration. Perle has “composition of matter” patents for the discovery of novel human beta regeneration peptides. Perle’s total intellectual property portfolio (IP) comprises 12 issued and pending patents all in the diabetes space. Perle’s IP is established around the usage of novel proprietary peptides and proton pump inhibitors for beta cell generation combined with immune tolerance agents, with the ultimate goal of eliminating the need for insulin injections for the diabetes patients. To learn more, please visit us at www.PerleBioscience.com.

Perle Bioscience Contact:
Dr. Ryan Fiorini
CEO & President
Perle Bioscience, Inc.
Email: drfiorini@perlebioscience.com

Media Contact:
Jenny Ferrara
Public Relations
Obviouslee Marketing
Email: jenny@obviouslee.com
Phone: 843-972-0712 x 131

# # #